ZyVersa Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2021 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
ZyVersa Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2021 to Q2 2024.
  • ZyVersa Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$2.76M, a 96.5% increase year-over-year.
  • ZyVersa Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$21.8M, a 73.6% increase year-over-year.
  • ZyVersa Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$98.3M, a 600% decline from 2022.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 -$2.76M +$75.7M +96.5% Jun 30, 2024 10-Q 2024-08-09
Q1 2024 -$2.83M +$717K +20.2% Mar 31, 2024 10-Q 2024-08-09
Q4 2023 -$13.3M -$13.3M -17680% Dec 31, 2023 10-K 2024-03-25
Q3 2023 -$2.9M -$2.22M -327% Sep 30, 2023 10-Q 2023-11-14
Q2 2023 -$78.5M -$78.1M -19845% Jun 30, 2023 10-Q 2024-08-09
Q1 2023 -$3.54M -$2.82M -392% Mar 31, 2023 10-Q 2024-08-09
Q4 2022 -$75K Dec 31, 2022 10-K 2024-03-25
Q3 2022 -$679K -$679K Sep 30, 2022 10-Q 2022-11-14
Q2 2022 -$394K -$393K Jun 30, 2022 10-Q 2022-11-14
Q1 2022 -$720K -$719K Mar 31, 2022 10-Q 2022-11-14
Q3 2021 -$174* Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$789* Jun 30, 2021 10-Q 2022-11-14
Q1 2021 -$1.11K* Mar 31, 2021 10-Q 2022-11-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.